<DOC>
	<DOCNO>NCT01554995</DOCNO>
	<brief_summary>Primary - To investigate safety tolerability LCB01-0371 single oral dose Secondary - To investigate pharmacokinetic characteristic LCB01-0371 single oral dose - To investigate safety LCB01-0371 single oral dose</brief_summary>
	<brief_title>A Clinical Study , Randomized , Double-blind , Placebo-controlled , Single Dose Study</brief_title>
	<detailed_description>- To investigate pharmacokinetic characteristic LCB01-0371 single oral dose - To investigate safety LCB01-0371 single oral dose</detailed_description>
	<mesh_term>Linezolid</mesh_term>
	<criteria>1 . Healthy Male 20 45 year age time screen 2 . Subjects body mass index ( BMI ) 20 27 time screen 3 . Agree continue use medically reliable dual contraception donate sperm 30th day study completion 4 . Capable give write informed consent , willing participate clinical trial , willing comply study requirement 1 . History liver , kidney , respiratory , musculoskeletal , endocrinologic , neuropsychiatric , hematooncologic , cardiovascular problem ( ) . 2 . History gastrointestinal problem ( e.g . Crohn 's disease , gastrointestinal ulcer ) affect absorption within 6 month screen 3 . History hypersensitivity clinically significant adverse drug reaction ( ) LCB010371 , class study drug ( linezolid ) , drug include aspirin antibiotic . 4 . History drug abuse positive result urine drug screen test 5 . AST , ALT , rGT , billirubin ( total ) value 1.5 time ULN</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>LCB01-0371</keyword>
</DOC>